Get the Stockscreener App
1.30
1.56%
0.02
Humacyte Inc stock is traded at $1.30, with a volume of 9.37M.
It is up +1.56% in the last 24 hours and up +58.54% over the past month.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$1.28
Open:
$1.28
24h Volume:
9.37M
Relative Volume:
1.33
Market Cap:
$288.62M
Revenue:
$2.04M
Net Income/Loss:
$-43.21M
P/E Ratio:
-6.2893
EPS:
-0.2067
Net Cash Flow:
$-105.93M
1W Performance:
+23.81%
1M Performance:
+58.54%
6M Performance:
-3.70%
1Y Performance:
-53.07%
1-Day Range:
$1.24
$1.34
1-Week Range:
$1.02
$1.34
52-Week Range:
$0.5469
$2.93
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.30 | 284.18M | 2.04M | -43.21M | -105.93M | -0.2067 |
VRTX
Vertex Pharmaceuticals Inc
|
447.54 | 113.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.78 | 65.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
835.99 | 52.14B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.98 | 40.73B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.48 | 32.87B | 742.00K | -1.37B | -1.07B | -7.0731 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Initiated | Barclays | Overweight |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Humacyte (HUMA) Is Up 23.8% After Long-Term Self-Repair Dialysis DataHas The Bull Case Changed? - Yahoo Finance
Humacyte, Inc. (HUMA) reports Q1 loss, misses revenue estimates - MSN
Humacyte, Inc. (HUMA) stock sinks as market gains: Here's why - MSN
Humacyte appoints Todd Rasmussen as chief surgical officer By Investing.com - Investing.com Nigeria
Wall Street bulls look optimistic about Humacyte, Inc. (HUMA): Should you buy? - MSN
Excited for this thing to really pop off - Moomoo
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $3 - Moomoo
HUMA Reiterates by HC Wainwright & Co. -- Price Target Maintained at $3.00 - GuruFocus
Humacyte Price Target Maintained With a $3.00/Share by HC Wainwright & Co. - Moomoo
Humacyte presents dialysis access vessel research at VASA meeting By Investing.com - Investing.com Nigeria
Humacyte presents dialysis access vessel research at VASA meeting - Investing.com
Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access - The Manila Times
Dialysis graft that self-repairs despite hundreds of needle sticks - Stock Titan
HUMA Technical Analysis | Trend, Signals & Chart Patterns | HUMACYTE INC (NASDAQ:HUMA) - ChartMill
Humacyte secures $1.5M Saudi order – why did HUMA stock crash to record low today? - MSN
Humacyte (HUMA) director Kathleen Sebelius purchases 56,818 shares at $0.88 - Stock Titan
Humacyte (HUMA) director adds 11,000 shares at about $0.89 - Stock Titan
Humacyte (HUMA) CFO executes 45,887-share sell-to-cover trade for RSU taxes - Stock Titan
Humacyte (HUMA) CMO executes 45,887-share tax sell-to-cover under 10b5-1 plan - Stock Titan
Humacyte’s Symvess added to VA hospital contract system - Investing.com UK
Humacyte’s Symvess added to VA hospital contract system By Investing.com - Investing.com South Africa
VA hospitals to get easier access to Humacyte Symvess product - Stock Titan
Why Humacyte, Inc. (HUMA) Price Target Was Raised Despite Early-Stage Commercialization - Insider Monkey
[144] Humacyte, Inc. SEC Filing - Stock Titan
Number of shareholders of Humacyte, Inc. – NASDAQ:HUMA - TradingView
HUMA Should I Buy - Intellectia AI
Analysts Conflicted on These Healthcare Names: Cullinan Management (CGEM), Humacyte (HUMA) and Revvity (RVTY) - The Globe and Mail
Humacyte, Inc. (HUMA) stock declines while market improves: Some information for investors - MSN
Does Humacyte’s (HUMA) Nasdaq Notice Quietly Reframe Its Financing Flexibility And Clinical Adoption Story? - simplywall.st
H.C. Wainwright reiterates Humacyte stock rating at buy, $3 target - Investing.com UK
Humacyte, Inc. (NASDAQ:HUMA) Q1 2026 Earnings Call Transcript - Insider Monkey
H.C. Wainwright reiterates Humacyte stock rating at buy, $3 target By Investing.com - Investing.com South Africa
Barclays Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
HUMACYTE ($HUMA) Releases Q1 2026 Earnings - Moomoo
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $1.5 - Moomoo
HUMA Financials: Income Statement, Balance Sheet & Cash Flow | Humacyte Inc - Stock Titan
Humacyte (NASDAQ: HUMA) posts Q1 2026 loss and flags going concern risk - Stock Titan
MSN Money - MSN
Humacyte, Inc. Stock 12‑Month Price Target Cut to $4.93, Implies 442% Upside - TradingView
Humacyte (HUMA) Q1 2026 Earnings Transcript - The Globe and Mail
Humacyte Releases Q1 2026 Financial Results - AlphaStreet
Humacyte Q1 2026 Earnings Call Transcript - MarketBeat
BTIG cuts Humacyte stock price target on revenue miss, slower ramp - Investing.com
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.37%
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):